Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Rhea-AI Summary

Galmed (NASDAQ: GLMD) announced a breakthrough brain-penetrating formulation of its SCD1 inhibitor Aramchol, co-developed with Barcode Nanotech, using lipid nanoparticles designed for subcutaneous delivery across the blood–brain barrier.

In vitro data show dose-dependent reduction of α-synuclein aggregation; Galmed plans a PoC Ph1b/2 study in Parkinson disease in H2 2026, subject to regulatory advice.

News Market Reaction – GLMD

+26.14% 1132.3x vol

23 alerts

+26.14% Session close to close

+85.6% Peak in 40 min

$5.37M Market Cap

1132.3x Rel. Volume

In the Apr 9 session, GLMD gained 26.14%, reflecting a significant positive market reaction. Argus tracked a peak move of +85.6% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 1132.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +26.1% in the session following this news. A strong positive reaction aligns with G...

Analysis

The stock surged +26.1% in the session following this news. A strong positive reaction aligns with GLMD’s history of favorable responses to Aramchol pipeline updates, where prior clinical and patent news saw moves of 3–8%. The new brain-penetrant formulation extends Aramchol into CNS indications, broadening its strategic scope. However, recent 20-F disclosures of continued losses and going-concern risk highlight that funding and execution remained key constraints even as the scientific story expanded.

Key Figures

Brain penetration gap: 98% of drugs Planned PD trial timing: H2 2026

2 metrics

Brain penetration gap 98% of drugs Do not reach the brain due to the blood–brain barrier

Planned PD trial timing H2 2026 Target start for PoC Phase 1b/2 study in Parkinson disease patients

Historical Context

5 past events · Latest: Mar 31 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 31	Annual report filing	Negative	+8.2%	20-F detailed ongoing losses and going-concern doubt while refocusing Aramchol.
Jan 30	Nasdaq compliance notice	Negative	-6.3%	Nasdaq notified GLMD of non-compliance with the $1.00 minimum bid requirement.
Dec 08	Conference abstract	Positive	+8.0%	Late-breaking HEP-DART abstract on Aramchol plus regorafenib in hepatocellular carcinoma.
Dec 04	Patent grant	Positive	+5.6%	New use patent for Aramchol plus Rezdiffra in MASH across multiple regions.
Dec 01	CEO shareholder letter	Positive	+3.7%	CEO outlined cash runway, Aramchol clinical data, and plans for new trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Over the last five news events, GLMD has typically traded higher on pipeline/patent updates, with only the Nasdaq bid-price notice producing a negative move. One divergence occurred when shares rose despite a 20-F highlighting losses and going-concern risk.

Recent Company History

In the past few months, GLMD news has centered on Aramchol and corporate positioning. A Dec 1, 2025 CEO letter highlighted cash of $19.2M and expansion plans, and subsequent patent and HEP-DART abstract updates in Dec 2025 drove price gains of 5.61% and 8.04%. A Nasdaq minimum bid notification on Jan 30, 2026 led to a -6.28% move, while the Mar 31, 2026 20-F, despite disclosing significant losses, saw shares rise 8.16%. Today’s CNS-focused Aramchol formulation continues the strategy of broadening its indications.

Key Terms

blood–brain barrier (bbb), central nervous system (cns), lipid nanoparticles, subcutaneous injection, +4 more

8 terms

blood–brain barrier (bbb) medical

"98% of drugs do not reach the brain, as the blood–brain barrier (BBB)..."

A protective, tightly regulated barrier of blood vessels and cells that controls which substances from the bloodstream can enter the brain, acting like a security checkpoint that blocks many chemicals and pathogens. For investors, the barrier matters because it determines whether a drug or diagnostic can actually reach and affect the brain; success or failure in crossing it strongly influences development costs, timelines, regulatory risk and potential market value for neurological therapies.

central nervous system (cns) medical

"separates peripheral blood circulation from the central nervous system (CNS)."

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

lipid nanoparticles medical

"sequestration of the Aramchol in lipid nanoparticles which will be administered..."

Lipid nanoparticles are tiny, fat-like capsules that carry and protect drug molecules or genetic material until they reach target cells, where they help the payload enter and work. Think of them as microscopic delivery trucks or soap bubbles that keep fragile cargo safe and steer it to the right address. Investors care because this delivery technology can make medicines more effective, shape manufacturing costs and capacity, create patent and regulatory value, and influence commercial potential for therapies.

subcutaneous injection medical

"lipid nanoparticles which will be administered by subcutaneous injection for delivery..."

A subcutaneous injection is a method of delivering a medicine or vaccine by inserting a small needle just under the skin into the thin layer of fat beneath the outer skin. For investors, administration by subcutaneous injection matters because it influences patient convenience, dosing frequency, manufacturing complexity and distribution costs, all of which affect how widely a treatment is adopted and how it is priced—like choosing a product that customers can easily use at home versus one that needs a clinic visit.

stearoyl-coa desaturase (scd1) medical

"Stearoyl-CoA desaturase (SCD1) has been identified as an important therapeutic target..."

Stearoyl‑CoA desaturase 1 (SCD1) is an enzyme that helps cells convert “hard” saturated fats into more flexible monounsaturated fats, similar to a factory machine that softens a rigid material so it can be used in different products. Investors watch SCD1 because it is a drug target and a marker for metabolic and cancer research; progress on therapies or tests involving SCD1 can materially affect the value of biotech and pharmaceutical companies.

α-synuclein (αsyn) medical

"diseases ... characterized by the aggregation of the protein α-synuclein (αSyn)."

α-synuclein (αsyn) is a small protein found mainly in brain cells that helps with normal cell processes but can misfold and stick together into clumps. Those clumps are linked to neurodegenerative diseases like Parkinson’s and are used as a target for diagnostic tests and new treatments; for investors, progress or setbacks in drugs, tests, or approvals tied to αsyn can directly affect company value and market opportunities. Think of it like a normally useful part that, when warped, jams the machine and becomes the focus of repair efforts.

in-vitro medical

"In-vitro studies have demonstrated that Aramchol effectively down-regulated..."

In-vitro means a laboratory test or experiment done outside a living organism, typically in a test tube, petri dish, or similar container. For investors, in-vitro results are early-stage evidence that a compound or process can work under controlled lab conditions; they can spark interest and influence valuation but carry higher uncertainty because success in a dish does not guarantee safety or effectiveness in people.

phase 1b/2 medical

"advance Aramchol to a PoC Ph1b/2 studies in PD patients in H2 2026."

Phase 1b/2 is a combined early-stage human study that first checks a drug’s safety and side effects in a small group and then expands to test whether it shows signs of working in patients. Think of it as a product test that first confirms it’s safe to use, then looks for early evidence of benefit; positive results can significantly reduce clinical risk and increase a company’s value, while negative results raise the opposite.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• 98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS).
• Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary formulation of Aramchol which targets the brain. By crossing the BBB, this new Aramchol formulation could become a disease modifying therapy for unmet chronic CNS diseases.
• Stearoyl-CoA desaturase (SCD1) has been identified as an important therapeutic target for CNS diseases (Parkinson disease and dementia) which are characterized by the aggregation of the protein α-synuclein (αSyn). In-vitro studies have demonstrated that Aramchol effectively down-regulated αSyn-aggregation in a dose dependent manner.

RAMAT-GAN, Israel, April 9, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today the breakthrough development of a brain penetrating new formulation of Aramchol. Crossing of the blood-brain barrier (BBB) is an essential step to achieve effective treatment effects in Parkinson disease (PD) and other CNS diseases. The new Aramchol formulation is characterized by sequestration of the Aramchol in lipid nanoparticles which will be administered by subcutaneous injection for delivery across the BBB.

This new Aramchol formulation was co-developed by Galmed and Barcode Nanotech, based on Barcode Nanotech's unique and proprietary platform which enables simultaneous screening of hundreds of different nanoparticle formulations in vivo, coupled with AI analysis tools to select the optimal delivery vehicle to the brain.

There are currently no disease-modifying therapies available for treatment of PD or related synucleinopathies such as multiple systems atrophy (MSA) and dementia with Lewy bodies (DLB). These diseases are each characterized by presence of Lewy bodies enriched in αSyn protein and are thus collectively known as synucleinopathies. Recent evidence from cell-based screens of αSyn toxicity has identified stearoyl-CoA desaturase 1 (SCD1) as a potential target for treatment of synucleinopathies.

Based on the evidence for the role of SCD1 inhibition in mitigating synucleinopathies, Galmed's breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor position Aramchol as an attractive therapeutic asset for synucleinopathies such as Parkinson disease, multiple systems atrophy (MSA), dementia and other CNS indications of unmet need.

Allen Baharaff, Galmed's Co-founder and CEO, commented: "The largest challenge in developing innovative CNS therapeutics is delivering these molecules to the brain. I am excited to report today the fruits of our collaboration with Barcode Nanotech, advancing our lead compound Aramchol as a first in class brain penetrating SCD1 inhibitor. Based on our preliminary in-vitro data which demonstrated that Aramchol dose-dependently down-regulated αSyn-aggregation as well as indicating that the treatment was not associated with toxicity, we believe that treatment with Aramchol could prevent the pathophysiological cascade that leads to αSyn-aggregation which induces a chronic inflammatory state that is associated with PD disease progression and severity. Subject to the regulatory advice we are now seeking, we are planning to advance Aramchol to a PoC Ph1b/2 studies in PD patients in H2 2026."

Ronen Eavri, Co-founder & CEO of Barcode Nanotech, commented: "Barcode Nanotech has developed a library of novel lipids for RNA and DNA, LNP-based delivery, through a unique in vivo & AI-based screening platform which allow simultaneously screening of hundreds of different nanoparticle formulations. Based on our proprietary platform and lipids library we have identified a unique formulation of Aramchol to cross the BBB and deliver the molecule to the brain. We look forward to continuing our collaboration with Galmed to develop target-specific selective delivery vehicles of Aramchol to enable precise target-site activity and release of this promising drug."

About Galmed Pharmaceuticals Ltd.:

We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for the treatment of liver diseases, and continue to actively advance Aramchol for the treatment of combination therapy for NASH. We are also seeking to develop Aramchol for certain oncological indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.

About Barcode Nanotech Ltd.:

Barcode Nanotech develops delivery solutions for RNA & DNA therapies through a unique multiplexed discovery platform. The Company's proprietary NeoRNA™ Targeting Technology enables efficient discovery and optimization of lipid-based nanoparticles (LNPs) through in silico & in vivo mass-screening. The solution combines the design of thousands of new lipids and LNPs, advanced AI tools and in vivo barcoding-based biodistribution analysis at a single cell resolution. Using this platform, Barcode has developed unique LNPs that can direct RNA and other therapies to cells in the brain, kidney, lungs and additional target organs. The company has an in-house lead drug development program and concurrently collaborates with biopharma companies to develop new therapies.

Forward-Looking Statements:

Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the potential synergistic effect of Aramchol, Stivarga^® and Metformin as a new fixed-dose combination treatment, the expected timing of clinical trials, future clinical development and creating value for investors and stakeholders. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 in greater detail under the heading "Risk Factors." Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Logo: https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-a-brain-penetrating-new-formulation-of-its-scd1-inhibitor-aramchol-302738096.html

SOURCE Galmed Pharmaceuticals Ltd.

FAQ

What did Galmed (GLMD) announce on April 9, 2026 about Aramchol?

Galmed announced a brain-penetrating nanoparticle formulation of Aramchol for CNS delivery. According to Galmed, the formulation uses lipid nanoparticles for subcutaneous dosing to cross the blood–brain barrier and target SCD1-related pathways implicated in synucleinopathies.

How did Aramchol perform in preclinical tests according to Galmed?

In vitro studies showed Aramchol dose-dependently reduced α-synuclein aggregation without observed toxicity. According to Galmed, these cell-based results support SCD1 inhibition as a potential therapeutic approach for Parkinson disease and related synucleinopathies.

What partnership enabled Galmed's new Aramchol brain formulation (GLMD)?

Galmed co-developed the formulation with Barcode Nanotech using an in vivo, AI-driven nanoparticle screening platform. According to Galmed, Barcode's library and AI tools identified an LNP formulation that delivers Aramchol across the blood–brain barrier.

When does Galmed plan to start clinical proof-of-concept studies for Aramchol (GLMD)?

Galmed plans to advance Aramchol to PoC Ph1b/2 studies in Parkinson disease in H2 2026, subject to regulatory advice. According to Galmed, regulatory interactions are underway before initiating patient studies in the second half of 2026.

What mechanism is Aramchol targeting for Parkinson disease according to Galmed?

Aramchol is repositioned as an SCD1 inhibitor intended to mitigate α-synuclein aggregation, a hallmark of synucleinopathies. According to Galmed, inhibiting SCD1 reduced αSyn aggregation in cell-based screens, supporting target rationale for CNS indications.

How will Galmed deliver the brain-penetrating Aramchol formulation in patients?

The company plans subcutaneous administration of Aramchol sequestered in lipid nanoparticles to achieve brain delivery. According to Galmed, this approach leverages LNP chemistry and in vivo screening to optimize transport across the blood–brain barrier.